Opiranserin hydrochloride (VVZ-149 hydrochloride) is a non-opioid and non-NSAID analgesic that acts as a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50 of 0.86 μM and 1.3 μM, respectively.

N-Hydroxysuccinimide (HOSu; 1-Hydroxy-2,5-pyrrolidinedione) is a crucial reagent that forms NHS esters via DCC-mediated carboxylic acid activation. These esters enable covalent protein/antibody coupling to surfaces through primary amine reactions. It also modifies microfluidic SPR sensors for bacterial pathogen detection.

MY‑1B is a covalent inhibitor of the RNA methyltransferase NSUN2, with an IC50 of 1.3 μM. MY‑1B stereoselectively targets the active‑site cysteine residue C271 of NSUN2 and can be used to probe the function of NSUN2 in RNA methylation‑related processes.

JNJ-9350 is a chemical probe that inhibits spermine oxidase (SMOX) with an IC50 of 0.01 μM. This compound also shows inhibitory activity against polyamine oxidase (PAO), exhibiting an IC50 of 0.79 μM. JNJ-9350 has potential applications in cancer research.

GPX4-IN-5 covalently inhibits GPX4 with an IC50 of 0.12 μM. This compound induces ferroptosis and exhibits anti-tumor activity. It has potential applications in triple-negative breast cancer (TNBC) research.

Famitinib (SHR1020), an orally active inhibitor of multi‑targeted kinase, which inhibits the activity of c‑Kit, VEGFR‑2, and PDGFRβ with IC50 of 2.3 nM, 4.7 nM, and 6.6 nM, respectively.

CDK4/6-IN-2 is a CDK4 and CDK6 inhibitor obtained from patent US20180000819A1 (Compound 1). It exhibits IC50 values of 2.7 nM for CDK4 and 16 nM for CDK6.

BBI-2779 is a potent, selective, and orally active inhibitor of CHK1 with an IC50 of 0.3 nM. It preferentially kills cancer cells containing extrachromosomal DNA (ecDNA) by inducing replication stress and cell death. In gastric cancer models with FGFR2 gene amplification on ecDNA, BBI-2779 suppresses tumor growth and prevents drug resistance.

AD1058 is an orally bioavailable ATR inhibitor with blood-brain barrier permeability (IC50 = 1.6 nM). It demonstrates antitumor effects through inhibition of tumor cell proliferation, induction of cell cycle arrest, and promotion of apoptosis. This compound is applicable for studies involving advanced malignancies and brain metastases.

360A stabilizes G-quadruplex structures and inhibits telomerase activity, showing an IC50 of 300 nM in TRAP-G4 assays.

σ1R/H3R ligand-1 is a dual σ1R/H3R antagonist with a σ1R Ki of 8.8 nM and an H3R Ki of 31.2 nM. Through the dual action of simultaneously antagonizing σ1R and H3R, σ1R/H3R ligand-1 exhibits potent dose-dependent analgesic activity in mouse models of visceral pain and neuropathic pain. σ1R/H3R ligand-1 can be used for the research of visceral pain and neuropathic pain.

ΔDi6S sodium is a chondroitin that can be isolated from chondroitin-4-sulfate in whale cartilage.

δ-Carboline is a nitrogen-containing heterocyclic compound, and its derivatives all exhibit anti-cancer and antibacterial activities.

γ-Linolenic acid NHS ester is a lipid metabolite of γ-Linolenic acid (GLA), which can serve as a synthetic intermediate or probe labeling reagent for the preparation of GLA conjugates. In practical applications, γ-Linolenic acid NHS ester can be conjugated with taxanes and polysaccharides to form dual-type conjugates for drug delivery purposes.

βGlcCer is a glycosphingolipid.

β-funaltrexamine (β-FNA) is a irreversible and selective μ opioid receptor antagonist that exhibits anti-inflammatory and neuroprotective effects. β-Funaltrexamine reduces TLR4 signaling, inhibits cytokine-induced iNOS activation and neuroinflammation, and ameliorates neuronal degeneration. β-funaltrexamine inhibits NF-κB signaling and chemokine expression in both human astrocytes and mice. β-funaltrexamine can be used for research on neurodegenerative diseases, such as stroke.

β-catenin-IN-9 is a β-catenin inhibitor. β-catenin-IN-9 induces apoptosis, cell cycle arrest, and inhibits migration, invasion, and epithelial-mesenchymal transition (EMT) in colorectal cancer cells. β-catenin-IN-9 suppresses the transcription of β-catenin and vimentin, and significantly inhibits β-catenin at the protein level. β-catenin-IN-9 can be used for the research of colorectal cancer.

β-Catenin modulator-9 (Compound IIa-2075) is a β-Catenin modulator. β-Catenin modulator-9 specifically targets the activity of the stable β-catenin pool and inhibits the Wnt signaling pathway. β-Catenin modulator-9 can be used in cancer-related research.

β-Aspartyl phosphate is a nucleoside metabolite.

α-Synuclein-IN-17 (Compound 10) is an α-Synuclein inhibitor, with an IC50 value of 9 μM. α-Synuclein-IN-17 exhibits potent inhibitory activity against both in-vitro assembled asyn fibrils and LBD brain tissue-amplified asyn fibrils. α-Synuclein-IN-17 can be used for the study of Parkinson's disease (PD) and Lewy Body Disease (LBD).

α-Synuclein aggregate binder 2 (Compound 1) is a specific alpha-synuclein binder with a Ki of 1.6 nM. α-Synuclein aggregate binder 2 has a weak binding affinity for β-amyloid aggregates with a Ki of 295 nM. α-Synuclein aggregate binder 2 can be used as a tracer in Parkinson's disease.

α-Obscurine derivative-1 (Compound 7) is a α-Obscurine derivative. α-Obscurine derivative-1 inhibits CaV3.1 ion channel current with an IC50 of 0.19 μM. α-Obscurine derivative-1 can be used in the research of neurological disorders.

α-Hydroxysalmeterol is a metabolite that can be formed via cytochrome P450 isoform 3A4-induced hydroxylation of Salmeterol. α-Hydroxysalmeterol is a potentially relevant urine biomarker to include when screening for Salmeterol misuse.

α-Glucosidase-IN-113 is an α-glucosidase inhibitor with an IC50 of 17.52 μM. α-Glucosidase-IN-113 shows antiglycating activity and inhibits advanced glycation end-product formation. α-Glucosidase-IN-113 can be used for the research of type 2 diabetes.

α-Glucosidase-IN-100 (compound 6) is a potent alpha glucosidase inhibitor. α-Glucosidase-IN-100 can be used to study metabolic diseases such as diabetes.

αGlcCer is a glycosphingolipid.

α-Amylase-IN-13 is an orally active, selective, brain-penetrant α-amylase inhibitor (IC50 = 0.71 μM). α-Amylase-IN-13 inhibits α-amylase through a mixed type of inhibition mechanism. α-Amylase-IN-13 leads to a significant reduction in blood glucose level in diabetic rats. α-Amylase-IN-13 causes significant histopathological improvements in the kidney, liver, and pancreas. α-Amylase-IN-13 can be used for the study of diabetic complications.

α5β1 integrin-IN-1 (compound 65) is a potent and selective α5β1 integrin inhibitor with a pIC50 of 9.4. α5β1 integrin-IN-1 displays >10000-fold selectivity for α5β1 over αVβ3 (pIC50 = 5.5). α5β1 integrin-IN-1 reduces airway smooth muscle (ASM) tension through the disruption of cellular tethering. α5β1 integrin-IN-1 exhibits excellent inhalation pharmacokinetics in rodent. α5β1 integrin-IN-1 can be used for asthma research.

α4β7 Integrin-IN-1 (Example 356) is a potent inhibitor of α4β7 integrin (integrin). Its ability to block the interaction between α4β7 integrin and MadCAM-1 (EC50) is 0.05 nM. α4β7 Integrin-IN-1 can be used for the study of inflammatory bowel disease.

α1A/1D-Adrenoceptor antagonist-1 (Compound 15) is a selective α1A/1D-adrenoceptor dual antagonist with IC50 values of 20.26 and 164.9 nM. α1A/1D-Adrenoceptor antagonist-1 shows an IC50 of 1912 nM for α1B-adrenoceptor.α1A/1D-Adrenoceptor antagonist-1 can be used for research of benign prostatic hyperplasia.